IMVT Logo

Immunovant, Inc. (IMVT) 

NASDAQ
Market Cap
$3.94B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
565 of 774
Rank in Industry
305 of 433

Largest Insider Buys in Sector

IMVT Stock Price History Chart

IMVT Stock Performance

About Immunovant, Inc.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is …

Insider Activity of Immunovant, Inc.

Over the last 12 months, insiders at Immunovant, Inc. have bought $0 and sold $10.86M worth of Immunovant, Inc. stock.

On average, over the past 5 years, insiders at Immunovant, Inc. have bought $33.63M and sold $7.93M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,526,316 shares for transaction amount of $58M was made by Roivant Sciences Ltd. () on 2023‑10‑02.

List of Insider Buy and Sell Transactions, Immunovant, Inc.

2024-11-20SaleChief Executive Officer
16,692
0.0111%
$25.45$424,811+2.04%
2024-11-20SaleChief Medical Officer
3,353
0.0022%
$25.45$85,334+2.04%
2024-11-20SaleChief Financial Officer
4,174
0.0028%
$25.45$106,228+2.04%
2024-11-20SaleChief Legal Officer
3,650
0.0024%
$25.45$92,893+2.04%
2024-10-23SaleChief Legal Officer
4,361
0.003%
$29.53$128,7800.00%
2024-10-23SaleChief Technology Officer
2,740
0.0019%
$29.53$80,9120.00%
2024-10-23SaleChief Medical Officer
3,189
0.0022%
$29.53$94,1710.00%
2024-10-16SaleChief Executive Officer
9,095
0.0063%
$28.79$261,845+0.72%
2024-10-16SaleChief Medical Officer
3,188
0.0022%
$28.79$91,783+0.72%
2024-10-16SaleChief Financial Officer
3,271
0.0023%
$28.79$94,172+0.72%
2024-10-16SaleChief Legal Officer
2,860
0.002%
$28.79$82,339+0.72%
2024-10-09SaleChief Executive Officer
4,460
0.0032%
$29.56$131,838-2.10%
2024-10-09SaleChief Financial Officer
5,162
0.0037%
$29.56$152,589-2.10%
2024-08-21SaleChief Executive Officer
15,068
0.0101%
$31.86$480,052-9.06%
2024-08-21SaleChief Development Officer
3,027
0.002%
$31.86$96,437-9.06%
2024-08-21SaleChief Medical Officer
3,027
0.002%
$31.86$96,437-9.06%
2024-08-21SaleChief Financial Officer
3,768
0.0025%
$31.86$120,045-9.06%
2024-08-21SaleChief Legal Officer
3,295
0.0022%
$31.86$104,976-9.06%
2024-07-24SaleChief Legal Officer
4,015
0.0027%
$27.76$111,4560.00%
2024-07-24SaleChief Technology Officer
2,813
0.0019%
$27.76$78,0890.00%

Insider Historical Profitability

88.18%
Butchko Julia G.Chief Development Officer
440959
0.3004%
$26.87122<0.0001%
MIGAUSKY GEORGE Vdirector
109808
0.0748%
$26.8711<0.0001%
Fromkin Andrew J.director
88658
0.0604%
$26.8711<0.0001%
Pande Atuldirector
83158
0.0567%
$26.8721+99.07%
Roivant Sciences Ltd.
79805331
54.3689%
$26.8750+39.82%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Fidelity Investments$247.36M5.247.66M-2.79%-$7.1M0.02
The Vanguard Group$209.31M4.446.48M+11.16%+$21.02M<0.01
BlackRock$144.65M3.074.48M-1.19%-$1.74M<0.01
State Street$117.67M2.493.64M+13.23%+$13.75M0.01
Perceptive Advisors$95.74M2.032.96M+27.28%+$20.52M0.06
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.